Investor relations  

genOway continues its international expansion

  • Creation of its subsidiary genOway Japan to more effectively penetrate the world’s third-largest preclinical research market and
  • Target €5–10 million in revenue as part of the Route50+ plan

March 25, 2026: Download the press release


Interview with Alexandre Fraichard: ‘Bioaster will help us gain a year.’

  • genOway achieved €21M in revenue in 2025 (-5%), impacted by a cautious market environment and a major commercial reorganization.
  • The company accepts this slowdown in order to deploy its “Route 50+data” strategic plan and accelerate growth through the partial acquisition of Bioaster (13 hires).
  • Profitability remains strong, with an EBITDA margin above 15% (16.9% in the first half of 2025), and operations in 28 countries serving 550 clients.


The ROUTE50+ strategic plan becomes ROUTE50+DATA with the acquisition of assets from an OMICS   platform (data science & AI)

  • ROUTE50+ becomes ROUTE50+DATA: genOway expands its strategic plan by integrating assets in data science, AI, and OMICS to enhance the predictability of preclinical data
  • Financing & acceleration: the acquisition of these assets is financed by a €7 million private placement, enabling the plan to be accelerated by approximately one year with an operational platform planned for early 2026
  • The company aims at an average organic growth of ~20% per year, at least €50 million in revenue by 2028, and an EBITDA margin > 15%

December 16, 2025: Dowload the press release


Accelerated development in China: genOway Shanghai as a growth driver for the Group

  • The genOway Shanghai joint venture is rapidly accelerating its development in China, with growth well above initial forecasts.
  • Its annualized revenue has approached ~€2 million in recent months and it is expected to reach profitability by the end of 2025
  • The goal is to double revenue in 2026 and contribute between €5 million and €10 million to genOway's overall   revenue by 2028

November 18, 2026: Download the press release


genOway Investor Presentation  

September 25, 2025: Download presentation

-----

Financial Calendar

Analysts

Financial Press Releases

Half-Year / Annual Reports and Reference Documents

Shareholder Documentation

Investor Presentations, Videos and Interviews

Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe